USP21

Ubiquitin carboxyl-terminal hydrolase 21

271 patent compounds predicted against USP21, 81 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18321066	0.57	10/20
SCHEMBL5173078	0.60	5/20
SCHEMBL7445861	0.46	5/20
SCHEMBL7445870	0.46	5/20
SCHEMBL12168554	0.46	5/20
SCHEMBL24843482	0.38	4/20
SCHEMBL22305742	0.33	4/20
SCHEMBL1168058	0.44	3/20
SCHEMBL5349521	0.38	3/20
SCHEMBL4845074	0.35	3/20
SCHEMBL4843020	0.34	3/20
Hydrochloric Acid (SCHEMBL4843515)	0.34	3/20
SCHEMBL26758070	0.46	2/20
SCHEMBL6585794	0.46	2/20
SCHEMBL27546176	0.46	2/20
SCHEMBL3467279	0.44	2/20
SCHEMBL6583446	0.42	2/20
SCHEMBL5349489	0.40	2/20
SCHEMBL5353449	0.40	2/20
SCHEMBL6580207	0.39	2/20

Germline variants in USP21 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full USP21 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to USP21 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicenter Vitamin E Trial in Aging Persons With Down Syndrome	PHASE3	COMPLETED
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults	PHASE3	WITHDRAWN
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）	PHASE3	NOT_YET_RECRUITING
A Study to Evaluate the Safety, Immunogenicity, and Efficacy of UB-612 COVID-19 Vaccine	PHASE2/PHASE3	WITHDRAWN
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients	PHASE2	WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants	PHASE1	COMPLETED
PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19	PHASE1	COMPLETED
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines.	PHASE1	WITHDRAWN
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome	nan	COMPLETED
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis	nan	UNKNOWN
A Natural History Study of Angelman Syndrome	nan	RECRUITING
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS	nan	COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Study of Blood Samples From High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2	nan	UNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome	nan	COMPLETED
NLRP3 Inflammasome and Physical Therapy in ICU-Acquired Weakness	nan	RECRUITING
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a USP21 binder may also engage these)

Protein	Name	Similarity
Q2KJ72	—	1.000	Q2KJ72 →
B2GUX4	—	1.000	B2GUX4 →
Q9QZL6	—	1.000	Q9QZL6 →
USP20	Ubiquitin carboxyl-terminal hydrolase 20	0.978	landscape →
A7Z056	—	0.975	A7Z056 →
Q7ZUM8	—	0.974	Q7ZUM8 →
Q9JLG8	—	0.974	Q9JLG8 →
Q5XGZ2	—	0.973	Q5XGZ2 →
Q9P2H5	—	0.973	Q9P2H5 →
Q8C6M1	—	0.973	Q8C6M1 →
A5PN09	—	0.972	A5PN09 →
Q8BL80	—	0.972	Q8BL80 →
Q7Z5H3	—	0.972	Q7Z5H3 →
Q0QWG9	—	0.970	Q0QWG9 →
A0JM59	—	0.970	A0JM59 →
Q62925	—	0.969	Q62925 →
P98174	—	0.969	P98174 →
A0FI79	—	0.969	A0FI79 →
Q8C2S0	—	0.969	Q8C2S0 →
Q8BUM9	—	0.969	Q8BUM9 →
A4D2P6	—	0.969	A4D2P6 →
Q5R5Z6	—	0.969	Q5R5Z6 →
GRB7	Growth factor receptor-bound protein 7	0.968	landscape →
P78524	—	0.968	P78524 →
P52734	—	0.968	P52734 →
Q70CQ4	—	0.967	Q70CQ4 →
Q6NS60	—	0.967	Q6NS60 →
Q6NTR6	—	0.967	Q6NTR6 →
O75808	—	0.966	O75808 →
Q99MU3	—	0.966	Q99MU3 →